This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Quinapril hydrochloride, Accuzide
Description: Accupril (Quinapril) belongs to a class of medications called angiotensin-converting enzyme (ACE) inhibitors. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor, angiotensin II. The effect of quinapril in hypertension and in congestive heart failure (CHF) appears to result primarily from the inhibition of circulating and tissue ACE activity, thereby reducing angiotensin II formation.
Quinapril inhibits the elevation in blood pressure caused by intravenously administeredangiotensin I, but has no effect on the pressor response to angiotensin II, norepinephrine orepinephrine.
Pink Sheet Accupril patent litigation
Pink Sheet April Supplemental Approvals
Pink Sheet October Supplemental Approvals
Additional information available to subscribers only: